Company Exact Sciences Corporation
Stocks
EXAS
US30063P1057
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 21/03/2026 am IST
|
5-day change | 1st Jan Change | ||
| 104.91 USD | +0.95% |
|
-.--% | +3.30% |
| 25/03 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index | CI |
| 25/03 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index | CI |
Business description: Exact Sciences Corporation
Number of employees: 7,150
Sales by Activity: Exact Sciences Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 176.71Cr | 208.43Cr | 249.98Cr | 275.89Cr | 324.7Cr |
Geographical breakdown of sales: Exact Sciences Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 165.72Cr | 196.65Cr | 234.65Cr | 256.98Cr | 302.31Cr |
Outside of United States | 11Cr | 12Cr | 15Cr | 19Cr | 22Cr |
Company details: Exact Sciences Corporation
Group companies: Exact Sciences Corporation
| Name | Category and Sector |
|---|---|
Medical/Nursing Services
|
Bio Diagnostics & Testing
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.95% | -.--% | +84.96% | +59.92% | 2TCr | |
| +4.16% | +3.04% | +49.37% | +94.17% | 7.42TCr | |
| -3.11% | -3.53% | +20.19% | +81.44% | 5.74TCr | |
| +0.89% | -0.63% | +2.17% | +36.19% | 4.76TCr | |
| +0.36% | +0.81% | +342.39% | +742.40% | 4.43TCr | |
| -0.96% | -4.50% | +24.96% | +35.38% | 4.25TCr | |
| -0.20% | -0.77% | +4.13% | +105.50% | 4.07TCr | |
| -0.54% | +2.93% | +9.31% | +50.41% | 3.1TCr | |
| -2.68% | +2.92% | +29.33% | +22.72% | 2.85TCr | |
| +0.05% | -1.64% | -8.14% | -11.37% | 2.43TCr | |
| Average | -0.11% | -0.53% | +55.87% | +121.68% | 4.11TCr | |
| Weighted average by Cap. | +0.16% | -0.80% | +58.32% | +134.44% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EXAS Stock
- Company Exact Sciences Corporation
Select your edition
All financial news and data tailored to specific country editions
